Online citations, reference lists, and bibliographies.
← Back to Search

Mitochondrial Complex I Deficiency In Parkinson's Disease

A. Schapira, J. Cooper, D. Dexter, J. Clark, P. Jenner, C. Marsden
Published 1989 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Abstract: The structure and function of mitochondrial respiratory‐chain enzyme proteins were studied postmortem in the substantia nigra of nine patients with Parkinson's disease and nine matched controls. Total protein and mitochondrial mass were similar in the two groups. NADH‐ubiquinone reductase (Complex I) and NADH cytochrome c reductase activities were significantly reduced, whereas succinate cytochrome c reductase activity was normal. These results indicated a specific defect of Complex I activity in the substantia nigra of patients with Parkinson's disease. This biochemical defect is the same as that produced in animal models of parkinsonism by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) and adds further support to the proposition that Parkinson's disease may be due to an environmental toxin with action(s) similar to those of MPTP.
This paper references
10.1016/s0021-9258(19)52451-6
Protein measurement with the Folin phenol reagent.
O. H. Lowry (1951)
10.1016/0076-6879(67)10046-3
[43] Preparation and properties of DPNH-coenzyme Q reductase (complex I of the respiratory chain)
Y. Hatefi (1967)
10.1016/0076-6879(67)10043-8
[40] Preparations of succinate—cytochrome c reductase and the cytochrome b-c1 particle, and reconstitution of succinate-cytochrome c reductase
T. King (1967)
Preparation and properties of DPNH-coenzyme Q reductase, Methods Enzymol
Y. Hatefi (1967)
Preparation and properties of DPNH - coenzyme Q reductase
Y. Hatefi (1967)
Preparation of succinate cytochrome c reductase and the cytochrome b - c , particle , and reconstitution of succinale cytochrome c reductase
E. KingT. (1967)
10.1038/227680A0
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
U. K. Laemmli (1970)
10.1042/BJ1250115
Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones.
H. G. Coore (1971)
10.1016/S0022-2836(75)80010-6
Repair of pyrimidine dimers in nuclear and mitochondrial DNA of yeast irradiated with low doses of ultraviolet light.
L. Prakash (1975)
10.1016/0165-1781(79)90006-4
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
G. Davis (1979)
10.1073/PNAS.76.9.4350
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
H. Towbin (1979)
Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets: procedure and some applications
J. Neurochern (1979)
10.1126/SCIENCE.6823561
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
J. Langston (1983)
Aprimate model ofparkinsonism: selective destruction of dopaminergic neurons in the pars compacts of the substantia nigra by MPTP
R S.Burns (1983)
10.1289/EHP.845537
Paraquat: model for oxidant-initiated toxicity.
J. Bus (1984)
10.1016/0006-8993(84)90777-7
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey
J. Langston (1984)
10.1016/0006-291X(84)90614-4
Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP.
J. Salach (1984)
dation of the neurotoxic amine MPTP by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP
I. SaIachJ. (1984)
Oxidation of the neurotoxic amine MPTP by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP
J I Saiach (1984)
10.1016/0024-3205(85)90146-8
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
W. Nicklas (1985)
10.1016/0304-3940(85)90580-4
Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity
R. Heikkila (1985)
10.1016/S0074-7696(08)61373-X
Animal mitochondrial DNA: an extreme example of genetic economy.
G. Attardi (1985)
10.1016/0748-5514(85)90025-X
Role of metals in oxygen radical reactions.
S. Aust (1985)
10.1016/0006-291X(85)91639-0
The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals.
J. Poirier (1985)
10.1073/PNAS.82.7.2173
Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
J. Javitch (1985)
Functional assignment of the unidentified reading frames of human mitochondria] DNA
A Chomyn (1985)
Dopaminergic toxicity of rotenone and the MPP ion after their stereotaxic administration to rats: implication for the mechanism of MPTP toxicity
W J. (1985)
Inhibition of NADHlinked oxidation in brain mitochondria by MPP’, a metabolite of the neurotoxin MPTP
J. Poirier (1985)
10.1016/s0021-9258(19)57434-8
Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria.
R. Ramsay (1986)
10.1016/0024-3205(86)90037-8
Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.
R. Ramsay (1986)
Energy dependent uptake of MPP + , the neurotoxic metabolite of MPTP , by mitochondria
M. Darley-UsmarV. (1986)
Energy driven uptake of MPP + by brain mitochondria mediates the neurotoxicity of MPTP
R. RamsayR. (1986)
10.1016/0014-5793(87)81200-0
Photolabelling of a mitochondrially encoded subunit of NADH dehydrogenase with [3H]dihydrorotenone
Fergus G.P. Earley (1987)
10.1111/j.1471-4159.1987.tb02909.x
A Dopaminergic Cell Line Variant Resistant to the Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine
T. Denton (1987)
10.1111/j.1471-4159.1987.tb03384.x
Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine
T. Singer (1987)
10.1016/S0140-6736(87)91361-4
INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN
D. Dexter (1987)
tolabelling of a mitochondrially encoded subunit of NADH dehydrogenase with [ 3 H ] dihydrorotenone
P. EarleyF.G. (1987)
Subfractionation of mitochondria and isolation of the proteins of oxidative phosphorylation
C I Ragan (1987)
Subfractionation of mitochondria and isolation of the proteins of oxidative phosphorylation , in Mitochondria , a Practical Approach (
I. RaganC. (1987)
Increased nigral iron content
C D. (1987)
A dopaminergic cell line variant resistant to the neurotoxin MPTP
T. Denton (1987)
Biochemical events in the development of parkinsonism induced by MPTP
N. Castagnoli (1987)
A dopaminergic cell line variant
B D.Howard (1987)
10.1016/0006-2952(88)90674-0
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro.
Z. Rossetti (1988)
10.1016/S0140-6736(88)91296-2
MOLECULAR BASIS OF MITOCHONDRIAL MYOPATHIES: POLYPEPTIDE ANALYSIS IN COMPLEX-1 DEFICIENCY
AnthonyH.V. Schapira (1988)
10.1073/PNAS.85.17.6465
Normal oxidative damage to mitochondrial and nuclear DNA is extensive.
C. Richter (1988)
10.1016/S0140-6736(88)91894-6
PRIMARY BILIARY CIRRHOSIS: IDENTIFICATION OF TWO MAJOR M2 MITOCHONDRIAL AUTOANTIGENS
S. Yeaman (1988)
10.1038/331717A0
Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies
I. Holt (1988)
10.1016/0022-2828(88)90316-1
Reoxygenation in perfused, hypoxic heart causes a mitochondrial complex I defect
D. L. Hardy (1988)
10.1007/BF00769638
Molecular defects of NADH-ubiquinone oxidoreductase (Complex I) in mitochondrial diseases
J. A. Morgan-Hughes (1988)
Free radicals , lipid peroxidation and MPTP - induced parkinsonism
D. DiMonte (1988)
Deletions 3 - 25
J. HoltI. (1988)
Primary biliary cirrhosis : identification of two major M 2 mitochondrial autoantigens
J. YeamanS. (1988)
10.1111/j.1471-4159.1989.tb09133.x
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
D. Dexter (1989)
Mitochondria 1 Complex I deficiency in Parkinson ’ s disease
V. SchapiraA.H. (1989)
Mitochondria1 Complex I deficiency in Parkinson's disease. Lancet i
A H V Schapira (1989)
( 1 985 ) Parkinsonism - inducing neurotoxin MPTP uptake of the metabolite MPP + by dopamine neurons explains selective toxicity
A. JavitchJ.
MPTP causes selective damage to the zona compacta of the substantia nigra in the squirrel monkey
W. LangstonJ.
985) Parkinsonism-inducing neurotoxin MPTP uptake of the metabolite MPP+ by dopamine neurons explains selective toxicity
J A Javitch
984) MPTP causes selective damage to the zona compacta of the substantia nigra in the squirrel monkey
J W Langston
1) Protein measurement with the Fohn phenol reagent
0 .HLowry
I990 of mitochondrial DNA in patients with mitochondrial myopathy
( 195 1 ) Protein measurement with the Fohn phenol reagent
H. Lowry0.
989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
D T Dexter



This paper is referenced by
10.1016/j.neuint.2021.105003
Biomaterials in the treatment of Parkinson's disease
U. Krishnan (2021)
10.1101/2021.03.18.21253875
Altered transcriptome-proteome coupling indicates aberrant proteostasis in Parkinson's disease
F. Dick (2021)
10.1016/j.neuint.2021.105009
Biochemical characterization of proliferative and differentiated SH-SY5Y cell line as a model for Parkinson's disease
H. Alrashidi (2021)
10.1016/b978-0-12-819621-2.00017-6
Mitochondrial drug delivery systems
W. B. Hubbard (2021)
10.1101/2021.02.02.429344
Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches
Eliona Tsefou (2021)
10.1016/j.redox.2021.101896
Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
L. Ma (2021)
10.1186/s12967-021-02909-z
Characterization of terminal-ileal and colonic Crohn’s disease in treatment-naïve paediatric patients based on transcriptomic profile using logistic regression
Ilkyu Park (2021)
10.1016/j.bbamcr.2021.118998
In vivo brain imaging of mitochondrial Ca2+ in neurodegenerative diseases with multiphoton microscopy.
M. Calvo-Rodriguez (2021)
10.1016/j.arr.2021.101263
Oxidative stress and regulated cell death in Parkinson’s disease
PA Dionísio (2021)
10.1007/978-1-0716-1270-5_19
Single-Cell Approaches for Studying the Role of Mitochondrial DNA in Neurodegenerative Disease.
Laura J. Bailey (2021)
10.1007/s12640-021-00362-w
Nanoemulsion Improves the Neuroprotective Effects of Curcumin in an Experimental Model of Parkinson's Disease.
Osmar Vieira Ramires Júnior (2021)
10.1038/s41380-021-01050-z
The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity
M. Frison (2021)
10.1093/toxsci/kfaa066
Coordinated action of miR-146a and Parkin gene regulate Rotenone-induced neurodegeneration.
A. Jauhari (2020)
10.3390/ijms21186520
Animal Model for Lower Urinary Tract Dysfunction in Parkinson’s Disease
T. Kitta (2020)
10.1016/j.jprot.2020.103779
The impact of rattlesnake venom on mice cerebellum proteomics points to synaptic inhibition and tissue damage.
Fabio Montoni (2020)
10.3390/ijms21145022
Role of RNA Oxidation in Neurodegenerative Diseases
Ziqian Liu (2020)
10.1038/s41598-020-70486-0
Deletion of DJ-1 in rats affects protein abundance and mitochondrial function at the synapse
Mohannad A. Almikhlafi (2020)
10.3390/cells9092037
Gateways for Glutamate Neuroprotection in Parkinson’s Disease (PD): Essential Role of EAAT3 and NCX1 Revealed in an In Vitro Model of PD
S. Piccirillo (2020)
10.1007/s00109-020-02004-8
Mitochondrial respiratory supercomplexes in mammalian cells: structural versus functional role
S. Javadov (2020)
10.1111/jnc.15154
The multi‐faceted role of mitochondria in the pathology of Parkinson’s disease
Dennison Trinh (2020)
10.1016/bs.irn.2020.02.009
Status and future directions of clinical trials in Parkinson's disease.
Grażyna Söderbom (2020)
10.3389/fnagi.2020.00012
Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease
R. Franco (2020)
10.1007/s10565-020-09561-1
Mediators of mitophagy that regulate mitochondrial quality control play crucial role in diverse pathophysiology.
Rudranil De (2020)
10.1016/j.expneurol.2019.113069
Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K
J. Cassereau (2020)
10.1134/S0006297920050090
α-Synuclein Overexpression in SH-SY5Y Human Neuroblastoma Cells Leads to the Accumulation of Thioflavin S-positive Aggregates and Impairment of Glycolysis
A. Melnikova (2020)
10.3390/ijms21051758
Biocomplexity and Fractality in the Search of Biomarkers of Aging and Pathology: Mitochondrial DNA Profiling of Parkinson’s Disease
A. Zaia (2020)
10.1016/bs.irn.2020.03.023
The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases.
Grażyna Söderbom (2020)
10.1038/s42003-020-1084-0
Nano-imaging trace elements at organelle levels in substantia nigra overexpressing α-synuclein to model Parkinson’s disease
L. Lemelle (2020)
10.1007/s00702-019-02133-6
6-Hydroxydopamine: a far from simple neurotoxin
D. Varešlija (2020)
10.1007/s12640-020-00264-3
Cell-Permeable Calpain Inhibitor SJA6017 Provides Functional Protection to Spinal Motoneurons Exposed to MPP+
S. Samantaray (2020)
10.1101/2020.03.09.984195
Mitochondria-mitochondria interaction networks show altered topological patterns in Parkinson’s disease
M. Zanin (2020)
10.1007/s11064-020-03058-3
Promising Polyphenols in Parkinson’s Disease Therapeutics
Ashutosh Kumar Singh (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar